Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $67.6 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
